Table 5 Cardiovascular morbidity in participants in the BELFRAIL cohort (n = 567)
| Â | n (%) | Objectified*, n (%) | Unknown$, n (%) |
|---|---|---|---|
Hypertension | 396 (70.1) | - | 2 (0.4) |
Hyperlipidaemia | 245 (44.0) | - | 3 (0.5) |
Diabetes | 107 (18.9) | - | 4 (0.7) |
Angina pectoris | 93 (16.5) | 58 (62.4) | 24 (4.3) |
Myocardial infarction | 62 (11.0) | 59 (95.2) | 6 (1.1) |
Cardiomyopathy | 56 (10.0) | - | - |
TIA | 58 (10.5) | 34 (58.6) | 9 (1.6) |
CVA | 46 (8.3) | 40 (87.0) | 5 (0.9) |
Peripheral arterial disease | 52 (9.2) | 43 (82.7) | 15 (2.7) |
Episode of decompensated heart failure | 60 (10.6) | 47 (78.3) | 7 (1.2) |
Episode of atrial fibrillation | 113 (20.1) | - | 5 (0.9) |
   Chronic atrial fibrillation | 58 (10.3) | - | - |
Valvular disease | 140 (24.9) | 135 (96.4) | 7 (1.2) |
Peripheral oedema | 237 (43.8) | - | 5 (0.9) |